Rivaroxaban (BAY59-7939, Xarelto)

DRUG2 trials

Sponsors

Bayer

Conditions

AtherosclerosisCoronary Artery DiseasePeripheral Artery Disease

Unknown Phase

Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid

CompletedNCT03746275

BayerAtherosclerosis

Start: 2018-11-13End: 2021-07-13Updated: 2022-05-02

A Study to Collect Data on the Treatment Pattern of Xarelto + Acetylsalicylic Acid in the Routine Clinical Practice in Patients Who Are Suffering From a Condition That Narrows the Blood Vessels Supplying the Heart and / or a Condition That Most Commonly Narrows the Blood Vessel in the Legs

CompletedNCT04401761

BayerCoronary Artery Disease, Peripheral Artery Disease

Start: 2020-05-28End: 2023-09-29Updated: 2023-10-25

Related Papers

Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both.

2020-01-2816 citations